Ritholtz Wealth Management Acquires 28,828 Shares of Pfizer Inc. $PFE

Ritholtz Wealth Management boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 32.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 117,836 shares of the biopharmaceutical company’s stock after purchasing an additional 28,828 shares during the quarter. Ritholtz Wealth Management’s holdings in Pfizer were worth $3,002,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Nwam LLC lifted its stake in shares of Pfizer by 7.5% during the 3rd quarter. Nwam LLC now owns 43,630 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 3,044 shares during the last quarter. Live Oak Investment Partners bought a new position in Pfizer in the 3rd quarter valued at about $357,000. Country Trust Bank boosted its holdings in shares of Pfizer by 10.3% during the third quarter. Country Trust Bank now owns 4,923 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 460 shares during the period. Gilliland Jeter Wealth Management LLC grew its position in shares of Pfizer by 17.9% in the third quarter. Gilliland Jeter Wealth Management LLC now owns 22,597 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 3,424 shares during the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. increased its stake in shares of Pfizer by 15.5% during the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 9,675 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 1,300 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. UBS Group began coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $27.88.

Pfizer Stock Performance

NYSE PFE opened at $25.68 on Friday. The firm’s 50 day simple moving average is $25.35 and its 200 day simple moving average is $24.99. The firm has a market capitalization of $146.01 billion, a price-to-earnings ratio of 14.93 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.